Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US9945862B2 · kind B2 · utility
5Cited by
82References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 31, 2012 |
| Grant date | Apr 17, 2018 |
| Priority date | — |
| Expiry date | Nov 12, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.